Hanmi Pharm sees strong sales and profit growth in 2023, driven by Rosuzet and China subsidiary. P3 trial for obesity drug is underway. Despite merger challenges, company poised for growth regardless
Boomeranged on Thu, 4 Apr 2024 13:09
Hanmi Pharm has submitted phase 1 clinical trial application for its next-generation obesity drug candidate HM15275 in the U.S., with an aim to commercialize the drug by 2030. In another development OCI-Hanmi merger has been called off, thereby removing the legal uncertainties. Lim brothers are reportedly in talks with another PE firm. Long-term investors can accumulate Hamni Pharm shares.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.